# Ligand Pharmaceuticals Incorporated (LGND)

Source: https://www.quantisnow.com/company/LGND
Generated: 2026-11-19T11:20:25.496Z

- Ticker: LGND
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000886163
- Website: ligand.com

## About

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

## Latest LGND news and filings

- 2026-11-16 21:24 UTC [SEC Form 4] [SEC Form 4 filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-4-filed-by-ligand-pharmaceuticals-incorporated-6794444)
- 2026-11-16 21:16 UTC [SEC Form 4] [Director Zimmermann Martine sold $636,336 worth of shares (2,000 units at $318.17), decreasing direct ownership by 53% to 1,782 units (SEC Form 4)](https://www.quantisnow.com/insight/director-zimmermann-martine-sold-636336-worth-of-shares-2000-units-6794199)
- 2026-11-12 21:49 UTC [SEC Form 4] [Director Aryeh Jason sold $960,141 worth of shares (3,000 units at $320.05), decreasing direct ownership by 3% to 105,476 units (SEC Form 4)](https://www.quantisnow.com/insight/director-aryeh-jason-sold-960141-worth-of-shares-3000-units-6788624)
- 2026-11-12 14:10 UTC [SEC Form 144] [SEC Form 144 filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-144-filed-by-ligand-pharmaceuticals-incorporated-6786902)
- 2026-11-06 22:41 UTC [SEC Form 4] [Director Aryeh Jason sold $90,237 worth of shares (282 units at $319.99), decreasing direct ownership by 0.26% to 108,476 units (SEC Form 4)](https://www.quantisnow.com/insight/director-aryeh-jason-sold-90237-worth-of-shares-282-units-6779630)
- 2026-11-04 21:23 UTC [SEC Form 4] [CLO & Secretary Reardon Andrew exercised 5,000 shares at a strike of $52.27 and sold $1,566,094 worth of shares (5,000 units at $313.22) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/clo-secretary-reardon-andrew-exercised-5000-shares-at-a-strike-6772987)
- 2026-11-04 00:39 UTC [SEC Form 4] [Director Aryeh Jason sold $676,158 worth of shares (2,111 units at $320.30), decreasing direct ownership by 2% to 108,758 units (SEC Form 4)](https://www.quantisnow.com/insight/director-aryeh-jason-sold-676158-worth-of-shares-2111-units-6770788)
- 2026-10-30 20:47 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ligand-pharmaceuticals-incorporated-6765479)
- 2026-10-29 11:14 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ligand-pharmaceuticals-incorporated-6762466)
- 2026-10-29 11:00 UTC [Earnings Date] [Ligand Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/ligand-reports-third-quarter-2026-financial-results-6762321)
- 2026-10-27 20:01 UTC [Conference Announcement] [Ligand to Participate in November Investor Conferences](https://www.quantisnow.com/insight/ligand-to-participate-in-november-investor-conferences-6759086)
- 2026-10-22 20:01 UTC [Ligand to Host Investor Day on December 8, 2026](https://www.quantisnow.com/insight/ligand-to-host-investor-day-on-december-8-2026-6754960)
- 2026-10-15 11:00 UTC [Earnings Date] [Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026](https://www.quantisnow.com/insight/ligand-to-report-third-quarter-2026-financial-results-on-october-6747164)
- 2026-10-06 20:35 UTC [SEC Form 4] [CLO & Secretary Reardon Andrew sold $1,520,346 worth of shares (5,000 units at $304.07) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/clo-secretary-reardon-andrew-sold-1520346-worth-of-shares-5000-6739165)
- 2026-09-25 12:33 UTC [Analyst Coverage Initiated] [Barclays initiated coverage on Ligand Pharma with a new price target](https://www.quantisnow.com/insight/barclays-initiated-coverage-on-ligand-pharma-with-a-new-price-6726112)
- 2026-09-24 21:22 UTC [SEC Form 4] [Director Zimmermann Martine covered exercise/tax liability with 115 shares, decreasing direct ownership by 3% to 3,782 units (SEC Form 4)](https://www.quantisnow.com/insight/director-zimmermann-martine-covered-exercisetax-liability-with-115-shares-decreasing-6725758)
- 2026-09-24 11:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ligand-pharmaceuticals-incorporated-6724810)
- 2026-09-24 11:00 UTC [Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million](https://www.quantisnow.com/insight/ligand-and-avencell-therapeutics-enter-financing-agreement-to-advance-pipeline-6724743)
- 2026-09-22 13:02 UTC [Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®](https://www.quantisnow.com/insight/sydnexis-announces-royalty-agreement-with-ligand-for-ryjunea-6722638)
- 2026-09-22 13:00 UTC [Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners](https://www.quantisnow.com/insight/primrose-bio-raises-significant-growth-capital-investment-led-by-signet-6722630)
- 2026-09-22 11:08 UTC [SEC Form 8-K] [Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ligand-pharmaceuticals-incorporated-filed-sec-form-8-k-regulation-fd-disclosure-6722327)
- 2026-09-22 11:00 UTC [Mergers & Acquisitions] [Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million](https://www.quantisnow.com/insight/ligand-acquires-royalty-and-milestone-interest-in-santens-ryjunea-from-6722281)
- 2026-09-14 20:59 UTC [SEC Form 4] [Director Zimmermann Martine sold $342,000 worth of shares (1,200 units at $285.00), decreasing direct ownership by 24% to 3,897 units (SEC Form 4)](https://www.quantisnow.com/insight/director-zimmermann-martine-sold-342000-worth-of-shares-1200-units-6714790)
- 2026-09-08 22:34 UTC [SEC Form 4] [CLO & Secretary Reardon Andrew sold $1,430,434 worth of shares (5,000 units at $286.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,514 units (SEC Form 4)](https://www.quantisnow.com/insight/clo-secretary-reardon-andrew-sold-1430434-worth-of-shares-5000-6708862)
- 2026-09-02 20:08 UTC [SEC Form 8-K] [Amendment: Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-ligand-pharmaceuticals-incorporated-filed-sec-form-8-k-financial-statements-6703130)
- 2026-08-26 11:00 UTC [Conference Announcement] [Ligand to Participate in September Investor Conferences](https://www.quantisnow.com/insight/ligand-to-participate-in-september-investor-conferences-6694905)
- 2026-08-14 21:05 UTC [SEC Form 4] [Chief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-espinoza-octavio-exercised-31641-shares-at-a-6683625)
- 2026-08-14 21:04 UTC [SEC Form 4] [Director Haas Jason exercised 6,138 shares at a strike of $51.56 and sold $2,090,062 worth of shares (7,138 units at $292.81), decreasing direct ownership by 20% to 3,981 units (SEC Form 4)](https://www.quantisnow.com/insight/director-haas-jason-exercised-6138-shares-at-a-strike-of-6683617)
- 2026-08-14 13:31 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Ligand Pharma](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-ligand-pharma-6682162)
- 2026-08-10 20:12 UTC [Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates](https://www.quantisnow.com/insight/orchestra-biomed-reports-second-quarter-2026-financial-results-and-highlights-6673730)
- 2026-08-07 20:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ligand-pharmaceuticals-incorporated-6671493)
- 2026-08-06 11:05 UTC [SEC Form 8-K] [Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ligand-pharmaceuticals-incorporated-filed-sec-form-8-k-results-of-operations-6667173)
- 2026-08-06 11:00 UTC [Earnings Date] [Ligand Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/ligand-reports-second-quarter-2026-financial-results-6667037)
- 2026-08-04 22:42 UTC [SEC Form 4] [CLO & Secretary Reardon Andrew sold $1,444,951 worth of shares (5,000 units at $288.99) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)](https://www.quantisnow.com/insight/clo-secretary-reardon-andrew-sold-1444951-worth-of-shares-5000-6663343)
- 2026-07-23 11:00 UTC [Earnings Date] [Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026](https://www.quantisnow.com/insight/ligand-to-report-second-quarter-2026-financial-results-on-august-6646111)
- 2026-07-22 20:52 UTC [SEC Form S-8] [SEC Form S-8 filed by Ligand Pharmaceuticals Incorporated](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-ligand-pharmaceuticals-incorporated-6645630)
- 2026-07-21 12:09 UTC [Analyst Coverage Resumed] [Citigroup resumed coverage on Ligand Pharma with a new price target](https://www.quantisnow.com/insight/citigroup-resumed-coverage-on-ligand-pharma-with-a-new-price-6643335)
- 2026-07-14 13:20 UTC [SEC Form 8-K] [Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/ligand-pharmaceuticals-incorporated-filed-sec-form-8-k-entry-into-a-6636358)
- 2026-07-14 13:00 UTC [Public Offering] [XOMA Royalty Announces Closing of Its Acquisition by Ligand](https://www.quantisnow.com/insight/xoma-royalty-announces-closing-of-its-acquisition-by-ligand-6636249)
- 2026-07-14 13:00 UTC [Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets](https://www.quantisnow.com/insight/ligand-completes-acquisition-of-xoma-royalty-creating-a-portfolio-of-6636241)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LGND
- Earnings history: https://www.quantisnow.com/earnings/LGND
- Dividend history: https://www.quantisnow.com/dividends/LGND
- Insider transactions: https://www.quantisnow.com/insiders/LGND
- Options chain: https://www.quantisnow.com/options/LGND
- SEC 8-K filings only: https://www.quantisnow.com/company/LGND/8-k
- RSS and alerts for LGND: https://www.quantisnow.com/docs/rss-feeds.md
